Abstract:
Objective To investigate the expression characteristics and clinical significance of FOXC1 in colon cancer, and decipher its molecular mechanism in regulating tumor cell proliferation and apoptosis.
Methods The GEPIA database was employed to analyze the expression of FOXC1 and its correlation with prognosis in colon cancer. Differential expression of FOXC1 was detected by qRT-PCR and Western blot in colon cancer cells (HCT116 and SW620) and normal colon epithelial cells (NCM460), and stable FOXC1-knockdown (sh-FOXC1) cell lines were established. Western blot, flow cytometry, CCK-8, and plate colony formation assays were performed to analyze the effects of FOXC1 knockdown on cell proliferation, cell cycle, and apoptosis. Furthermore, the downstream signaling pathway was verified using Rap1 overexpression rescue experiments.
Results FOXC1 mRNA expression was significantly higher in colon cancer tissues than in normal tissues (P<0.001). FOXC1 overexpression was nearing significance in relation to tumor staging (P=0.053), and patients with high FOXC1 expression had a shorter overall survival (Log-rank P=0.013). After FOXC1 knockdown, the expression of CyclinD1 and Bcl-2 decreased, whereas the expression of Bax increased (P<0.01). The proportion of cells in the G0/G1 phase increased, while the proportion of cells in the S phase decreased (P<0.001), and the cell proliferation activity and number of colonies formed decreased (P<0.001). Mechanistic studies demonstrated that after FOXC1 knockdown, Rap1 expression was reduced, while the expression of Rap1GAP increased (P < 0.05). After restoration of Rap1 expression in FOXC1-knockdown cells, the downregulation of CyclinD1 and Bcl-2 expression and the increase in Bax expression were reversed (P<0.05), the S phase ratio was increased (P<0.05), and cell proliferation activity and colony formation abilities were also rescued.
Conclusion FOXC1 promotes colon cancer progression by facilitating Rap1 expression and downregulating Rap1GAP. Targeted intervention of the FOXC1-Rap1 signaling axis may emerge as a potential therapeutic strategy.